Research Letter

Eosinophilic Annular Erythema Due to Certolizumab Pegol Therapy for Rheumatoid Arthritis Post-COVID-19 Vaccine

Author Affiliation(s)



1. Capogrosso Sansone A, Mantarro S, Tuccori M, et al. Safety Profile of Certolizumab Pegol in Patients with Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-Analysis. Drug Saf. 2015;38(10):869-888. DOI: 10.1007/s40264-015-0336-2. PMID: 26316054. 2. Klein RQ, Spivack J, Choate KA. Psoriatic skin lesions induced by certolizumab pegol. Arch Dermatol. 2010;146(9):1055-1056. DOI: 10.1001/archdermatol.2010.225. PMID: 20855720. 3. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharacol Ther. 1981;30:239–245. DOI: 10.1038/clpt.1981.154. PMID: 7249508. 4. Maione V, Caravello S, Cozzi C, et al. Refractory eosinophilic annular erythema treated successfully with dupilumab. J Dtsch Dermatol Ges. 2020;18(9):1031-1032. DOI: 10.1111/ddg.14254. PMID: 32909389. 5. Heras MO, Muñoz NP, Sancho MI, et al. Eosinophilic annular erythema in adults: report of two cases and review of the literature. An Bras Dermatol. 2017;92(5 Suppl 1):65-68. DOI: 10.1590/abd1806-4841.20176373. PMID: 29267450. PMCID: PMC5726681. 6. Bassi A, Scarfi F, Galeone M, et al. Generalized granuloma annulare and non-Hodgkin’s lymphoma. Acta Derm Venereol. 2013;93(4):484-485. DOI: 10.2340/00015555-1510. PMID: 23250047.

Send mail to Author

Send Cancel